摘要
目的:对"蒂达"各品种不同基原植物药用合理性及其资源利用价值作出评价。方法:采用HPLC指纹图谱共有特征峰、结合SPSS聚类分析方法,评价"蒂达"不同品种基原植物的成分组成相似性。结果:"蒂达"不同品种涉及的来源有龙胆科獐牙菜属、花锚属、扁蕾属及肋柱花属共15种1变种33个样品,指纹图谱全谱相似度较差;以10个共有峰成分的相对面积聚类,其基原植物可分别聚为4个组;上述4个属的属间成分组成差异较大;其中獐牙菜属不同种间成分组成变化较大,而其他各属种间成分组成相似度较高。结论:上述龙胆科4属植物均含有具有保肝利胆生物活性的环烯醚萜类、酮类及三萜类成分,藏医学将其归为"蒂达"一类药材使用具有一定的物质基础;鉴于"蒂达"类药材不同基原各品种间在成分组成上差异较大,分别制定各品种的HPLC指纹图谱,是鉴别和控制各品种质量的有效手段,可有效控制各基原品种质量。
Objective: To evaluate the medicinal reasonableness and resource utilization of Dida from different species. Method: With common characteristic absorption peaks of HPLC fingerprints and SPSS cluster, the composition similarity of Dida from different species was evaluated. Result: The composition similarity of HPLC fingerprints of 33 Dida samples from 15 species and 1 variety originated from Swertia, Halenia, Gentianopsis, Lomatogonium was difference. The original species can be clustered into four groups by the relative area of 10 common characteristic peaks of HPLC fingerprints. The compositions of four different genera are quite different. Conclusion: Because of containing iridoids, xanthones, and triterpenes which have liver protection and cholagogue functions, all of species from Swertia, Halenia, Gentianopsis and Lomatogonium in Gentianaceae are classified as Dida in Tibetan medicine. According to the composition difference among different species, the HPLC fingerprints established for Dida from different source are an effective means to identify nd control the quality of Dida.
出处
《中国中药杂志》
CAS
CSCD
北大核心
2012年第17期2639-2645,共7页
China Journal of Chinese Materia Medica
基金
国家科技支撑计划项目(2006DA106A11-12)
创新药物孵化基地项目(2010ZX09401-306-3-9)